In most recent advancements, RNA editing uses the CRISPR-Cas13 system, a newer technique that was created specifically to help develop therapies that work with RNA. DNA editing is permanent, which ...

Mammalian RNAs can be edited by the conversion of adenosine to inosine, which is read as guanosine, but technological constraints have limited our view of the overall contribution of RNA editing ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

“RNA editing is very powerful technologically,” says Takahiro Nakamura, a plant molecular biologist at Kyushu University in Fukuoka, Japan, who also serves as the chief scientific officer at ...

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.

ProQR (PRQR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP ...

ProQR ( ) just unveiled an announcement. ProQR Therapeutics announced significant advancements in their Axiomer RNA-editing platform during their 2024 Investor and Analyst Event.

New research has identified a critical fall-back mechanism used by the cells when the usual RNA editing process is switched off. Professor Carl Walkley heads the RNA Biology and Innate Immune ...

The researchers for the first time used an RNA editing tool—known as CRISPR Cas13—to suppress the production of Vascular ...

At the Breakthroughs in Muscular Dystrophy special meeting held in Chicago Nov. 19-20, 2024, and organized by the American Society of Gene & Cell Therapy (ASGCT), multiple interventions at the RNA ...

ProQR Therapeutics announced significant advancements in their Axiomer RNA-editing platform during their 2024 Investor and Analyst Event. The company highlighted the platform’s potential to ...

The company's approach to RNA editing has garnered attention from both the scientific community and potential pharmaceutical partners. WaVe's HD program has faced a significant setback with Takeda ...